Quantcast

Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.

Research paper by Ahmed A Almradi, Jurij J Hanzel, Rocio R Sedano, Claire E CE Parker, Brian G BG Feagan, Christopher C Ma, Vipul V Jairath

Indexed on: 27 Oct '20Published on: 27 Oct '20Published in: BioDrugs



Abstract

The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn's disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation. Many pathways driving inflammation have been described, and different pathways may predominate in an individual patient. The interleukin (IL)-23 pathway plays a key role in IBD pathogenesis through promoting a pathological Th17 response. Targeting IL-23 is effective in the treatment of IBD. Ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12/23, is approved for treatment of moderate-to-severe CD and UC. Specific IL-23p19 antagonists are in development and promising results from phase II trials of mirikizumab and risankizumab underscore the potential for this class of treatment. In this review, we summarize the mechanisms of action and the evidence from clinical trials supporting the efficacy and safety of different IL-23 antagonists for IBD.